Stories from the dialysis comunity across the globe.
Study finds wide geographic variability in organ donation rates - NephrologyNews.com
Organ donation consent rates are highest in the Midwest and lowest in New York State, according to a study by researchers from the Perelman School of Medicine at the University of Pennsylvania and the University of Kansas Hospital. The study, published in the American Journal of Transplantation, shows wide variation in the number of eligible organ donors whose loved ones consent to organ donation across the country. More than 123,000 Americans are currently waiting for organ transplants, and 21 patients die each day because there aren't enough organs to go around.
"These findings dispute the commonly held notion that the gap in donor supply in certain geographic areas is due to large populations of racial and ethnic minorities who are less likely to consent for donation, thus affecting the geography of available organs," said the study's lead author, David Goldberg, MD, MSCE, an assistant professor in the division of Gastroenterology at Penn.
The researchers examined data from the Organ Procurement and Transplantation Network (OPTN)/United Network for Organ Sharing (UNOS), the nation's organ transplant network, on all reported eligible deaths, defined as potential brain-dead organ donors age 70 years or less without any medical conditions precluding donation, from 2008 to 2013. Of 52,571 eligible patient deaths reported to UNOS, consent for donation was obtained in 73% of cases. Consent rates were highest among potential donors under the age of 55, white patients, and when the referral from the local hospital was made in a "timely" manner.
Consent rates along racial lines echoed findings from earlier studies: lower among African Americans, Hispanics, and Asians, when compared to Caucasian patients. Yet these lower consent rates among racial and ethnic minorities did not explain the overall geographic variability in consent rates. Even after accounting for patient and geographic factors of the potential donors, the study found that the donor consent rates among the 58 donor service areas (DSA) ranged from a 64% to 90%.
Although the average consent rate within each donor service area, when accounting for the race/ethnicity and other factors among the eligible deaths, was between 75 and 80%, the consent rates fell below 70% in nearly a quarter of the donor service areas. Even when examining only one racial group at a time, the researchers found wide variation in donation rates across the nation's donor service areas: consent rates among Caucasian patients, for example, ranged from 72 to 92% across the 58 donor service areas.
"These data demonstrate that although the underlying demographics of the donor population may contribute to geographic differences in organ consent rates, it clearly is not the major driving factor," Goldberg said. "Although there may be underlying cultural or religious differences leading to variable consent rates, the dramatic differences in consent rates among younger Caucasians clearly show that race alone cannot explain geographic differences in organ donor consent rates."
The authors note that if consent rates over five and a half years in the geographic areas with the lowest consent rates were to increase to the current level of the geographic area with the median level of donors identified, there could potentially be 773 more donors available. That pool could yield nearly 2,700 lifesaving kidney, liver, lung, heart, pancreas, and/or intestine transplants.
"Importantly, nearly one third of these increased donors would come from the donor service areas in New York State," Goldberg said. "This is of critical importance to the liver transplant community, the OPTN, and HRSA, as there are proposals currently being evaluated to redraw the maps for how organs are distributed. Yet efforts to increase donation rates, most notably in New York, would save more lives, increase the number of transplants, and potentially cost much less than efforts to more broadly share organs across the nation."
"With over 10,000 patients a year dying on a transplant waiting list or becoming too sick to undergo a transplant, these data highlight the potential opportunity to save hundreds of more lives each year by increasing consent rates among potential organ donors," says senior author Richard Gilroy, MD, medical director of Liver Transplantation at the University of Kansas Hospital. "By increasing organ donor consent rates, and optimizing how we utilize a scarce resource, the transplant community can help OPTN achieve its highest priority of increasing the number of transplants each year in the US."
The researchers note that these data alone do not capture all potential deceased organ donors in the U.S., as the current definition of an eligible death excludes potential donors over age 70, and those classified as a "donation after cardiac death" donor, both of which broaden the pool of available donors. "However," Goldberg pointed out, "this group of patients represents the vast majority of actual organ donors in the United States."
The researchers conclude that the best way to boost organ donation rates is a multi-pronged approach that includes education and engagement with potential donors and their families, broader community engagement, concerted efforts by hospitals caring for potential donors, and optimized performance of organ procurement organizations who manage organ donation in this country.
"Efforts to increase organ donor consent rates by all parties should be a major focus of the transplant community and the general public," Goldberg said. "This is the only mechanism that will allow us to prevent waitlist deaths while increasing the number of transplants."
MINNEAPOLIS, May 28, 2015 /PRNewswire/ -- DaVita Clinical Research (DCR), a specialty contract research organization with services spanning a broad spectrum of drug and device development, today announced an expansion of its clinical trials capabilities in Europe.
Through expansion in Europe, DCR will be able to facilitate the conduct of late phase clinical trials in several medical centers outside of the U.S. for the first time. Physician leaders from Germany, Poland and Portugal with a combined 20 years of research experience will collaborate with DCR to provide data and knowledge-based insights to its clients.
"Together our American and European teams provide unique expertise in clinical research," said Amy Young, vice president and general manager of DCR. "Combining extensive nephrology and clinical trial experience with knowledge of local differences in the practice of nephrology positions us as a valuable resource in drug development for chronic kidney disease management."
DCR has been involved in developing every end stage renal disease drug approved by the U.S. Federal Drug Administration in the last 15 years. Individuals with advanced kidney disease typically have comorbidities, which may cause health complications. Clinical research is a necessary step in providing high quality care to patients with impaired kidney function.
"We have an experienced group of research physicians in our organization," said Bjorn Englund, DaVita HealthCare Partners president for Europe and the Middle East. "It's important that we apply their expertise as a resource to advance care for our patients."
DCR has conducted Phase I clinical trials in the U.S. since 1985, expanding its capabilities to include late phase clinical research, real-world health care data, health economics and outcomes research and medical communications over the past 30 years.
DaVita Clinical Research and DCR are registered trademarks of DaVita Healthcare Partners Inc.
CIO, CTO & Developer Resources
About DaVita HealthCare Partners DaVita HealthCare Partners Inc. (NYSE: DVA), a Fortune 500® company, is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of March 31, 2015, DaVita Kidney Care operated or provided administrative services at 2,197 outpatient dialysis centers located in the United States serving approximately 174,000 patients. The company also operated 93 outpatient dialysis centers located in 10 countries outside the United States. HealthCare Partners manages and operates medical groups and affiliated physician networks in Arizona, California, Nevada, New Mexico, Florida and Colorado in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. As of March 31, 2015 HealthCare Partners provided integrated care management for approximately 830,000 patients. For more information, please visit DaVitaHealthCarePartners.com.
About DaVita Clinical Research (DCR) DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita HealthCare Partners, Inc.,uses its extensive, applied database and real-world health care experience to assist pharmaceutical and medical device companies in the design, recruitment and completion of retrospective, prospective and pragmatic clinical trials. DCR's scientific and clinical expertise spans the lifecycle of product development with more than 175 client companies. DCR's early clinical research unit (Phase I-IIa) and late phase clinical research (Phase IIb through post-marketing) network of physicians and investigative sites, real-world health care data, health economics and outcomes research, and medical communications are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit www.davitaclinicalresearch.com.
DaVita Clinical Research Expands Nephrology Clinical Trial Capabilities in ... - Military Technologies
MINNEAPOLIS, May 28, 2015 /PRNewswire/ -- DaVita Clinical Research (DCR), a specialty contract research organization with services spanning a broad spectrum of drug and device development, today announced an expansion of its clinical trials capabilities in Europe.
Through expansion in Europe, DCR will be able to facilitate the conduct of late phase clinical trials in several medical centers outside of the U.S. for the first time. Physician leaders from Germany, Poland and Portugal with a combined 20 years of research experience will collaborate with DCR to provide data and knowledge-based insights to its clients.
"Together our American and European teams provide unique expertise in clinical research," said Amy Young, vice president and general manager of DCR. "Combining extensive nephrology and clinical trial experience with knowledge of local differences in the practice of nephrology positions us as a valuable resource in drug development for chronic kidney disease management."
DCR has been involved in developing every end stage renal disease drug approved by the U.S. Federal Drug Administration in the last 15 years. Individuals with advanced kidney disease typically have comorbidities, which may cause health complications. Clinical research is a necessary step in providing high quality care to patients with impaired kidney function.
"We have an experienced group of research physicians in our organization," said Bjorn Englund, DaVita HealthCare Partners president for Europe and the Middle East. "It's important that we apply their expertise as a resource to advance care for our patients."
DCR has conducted Phase I clinical trials in the U.S. since 1985, expanding its capabilities to include late phase clinical research, real-world health care data, health economics and outcomes research and medical communications over the past 30 years.
DaVita Clinical Research and DCR are registered trademarks of DaVita Healthcare Partners Inc.
About DaVita HealthCare Partners DaVita HealthCare Partners Inc. (NYSE: DVA), a Fortune 500® company, is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of March 31, 2015, DaVita Kidney Care operated or provided administrative services at 2,197 outpatient dialysis centers located in the United States serving approximately 174,000 patients. The company also operated 93 outpatient dialysis centers located in 10 countries outside the United States. HealthCare Partners manages and operates medical groups and affiliated physician Networks in Arizona, California, Nevada, New Mexico, Florida and Colorado in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. As of March 31, 2015 HealthCare Partners provided integrated care management for approximately 830,000 patients. For more information, please visit DaVitaHealthCarePartners.com.
About DaVita Clinical Research (DCR) DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita HealthCare Partners, Inc.,uses its extensive, applied database and real-world health care experience to assist pharmaceutical and medical device companies in the design, recruitment and completion of retrospective, prospective and pragmatic clinical trials. DCR's scientific and clinical expertise spans the lifecycle of product development with more than 175 client companies. DCR's early clinical research unit (Phase I-IIa) and late phase clinical research (Phase IIb through post-marketing) network of physicians and investigative sites, real-world health care data, health economics and outcomes research, and medical communications are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit www.davitaclinicalresearch.com.
Media Contact:
Bianca Violante
Office: (303) 876-6614 Mobile: (443) 417-6044
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
DaVita Clinical Research Expands Nephrology Clinical Trial Capabilities in ... - PR Newswire (press release)
DaVita Clinical Research and Pyxant Labs to Collaborate on Clinical Trials.
MINNEAPOLIS, May 28, 2015 /PRNewswire/ -- DaVita Clinical Research (DCR), a specialty contract research organization with services spanning a broad spectrum of drug and device development, today announced an expansion of its clinical trials capabilities in Europe.
Through expansion in Europe, DCR will be able to facilitate the conduct of late phase clinical trials in several medical centers outside of the U.S. for the first time. Physician leaders from Germany, Poland and Portugal with a combined 20 years of research experience will collaborate with DCR to provide data and knowledge-based insights to its clients.
"Together our American and European teams provide unique expertise in clinical research," said Amy Young, vice president and general manager of DCR. "Combining extensive nephrology and clinical trial experience with knowledge of local differences in the practice of nephrology positions us as a valuable resource in drug development for chronic kidney disease management."
DCR has been involved in developing every end stage renal disease drug approved by the U.S. Federal Drug Administration in the last 15 years. Individuals with advanced kidney disease typically have comorbidities, which may cause health complications. Clinical research is a necessary step in providing high quality care to patients with impaired kidney function.
"We have an experienced group of research physicians in our organization," said Bjorn Englund, DaVita HealthCare Partners president for Europe and the Middle East. "It's important that we apply their expertise as a resource to advance care for our patients."
DCR has conducted Phase I clinical trials in the U.S. since 1985, expanding its capabilities to include late phase clinical research, real-world health care data, health economics and outcomes research and medical communications over the past 30 years.
DaVita Clinical Research and DCR are registered trademarks of DaVita Healthcare Partners Inc.
About DaVita HealthCare Partners DaVita HealthCare Partners Inc. (NYSE: DVA), a Fortune 500® company, is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of March 31, 2015, DaVita Kidney Care operated or provided administrative services at 2,197 outpatient dialysis centers located in the United States serving approximately 174,000 patients. The company also operated 93 outpatient dialysis centers located in 10 countries outside the United States. HealthCare Partners manages and operates medical groups and affiliated physician networks in Arizona, California, Nevada, New Mexico, Florida and Colorado in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. As of March 31, 2015 HealthCare Partners provided integrated care management for approximately 830,000 patients. For more information, please visit DaVitaHealthCarePartners.com.
About DaVita Clinical Research (DCR) DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita HealthCare Partners, Inc.,uses its extensive, applied database and real-world health care experience to assist pharmaceutical and medical device companies in the design, recruitment and completion of retrospective, prospective and pragmatic clinical trials. DCR's scientific and clinical expertise spans the lifecycle of product development with more than 175 client companies. DCR's early clinical research unit (Phase I-IIa) and late phase clinical research (Phase IIb through post-marketing) network of physicians and investigative sites, real-world health care data, health economics and outcomes research, and medical communications are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit www.davitaclinicalresearch.com.
Media Contact:
Bianca Violante
Office: (303) 876-6614
Mobile: (443) 417-6044
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
DaVita Clinical Research Expands Nephrology Clinical Trial Capabilities in ... - MarketWatch
MINNEAPOLIS, May 28, 2015 /PRNewswire/ -- DaVita Clinical Research (DCR), a specialty contract research organization with services spanning a broad spectrum of drug and device development, today announced an expansion of its clinical trials capabilities in Europe.
Through expansion in Europe, DCR will be able to facilitate the conduct of late phase clinical trials in several medical centers outside of the U.S. for the first time. Physician leaders from Germany, Poland and Portugal with a combined 20 years of research experience will collaborate with DCR to provide data and knowledge-based insights to its clients.
"Together our American and European teams provide unique expertise in clinical research," said Amy Young, vice president and general manager of DCR. "Combining extensive nephrology and clinical trial experience with knowledge of local differences in the practice of nephrology positions us as a valuable resource in drug development for chronic kidney disease management."
DCR has been involved in developing every end stage renal disease drug approved by the U.S. Federal Drug Administration in the last 15 years. Individuals with advanced kidney disease typically have comorbidities, which may cause health complications. Clinical research is a necessary step in providing high quality care to patients with impaired kidney function.
"We have an experienced group of research physicians in our organization," said Bjorn Englund, DaVita HealthCare Partners president for Europe and the Middle East. "It's important that we apply their expertise as a resource to advance care for our patients."
DCR has conducted Phase I clinical trials in the U.S. since 1985, expanding its capabilities to include late phase clinical research, real-world health care data, health economics and outcomes research and medical communications over the past 30 years.
DaVita Clinical Research and DCR are registered trademarks of DaVita Healthcare Partners Inc.
About DaVita HealthCare PartnersDaVita HealthCare Partners Inc.
DVA, +0.20%
a Fortune 500® company, is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of March 31, 2015, DaVita Kidney Care operated or provided administrative services at 2,197 outpatient dialysis centers located in the United States serving approximately 174,000 patients. The company also operated 93 outpatient dialysis centers located in 10 countries outside the United States. HealthCare Partners manages and operates medical groups and affiliated physician networks in Arizona, California, Nevada, New Mexico, Florida and Colorado in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. As of March 31, 2015 HealthCare Partners provided integrated care management for approximately 830,000 patients. For more information, please visit DaVitaHealthCarePartners.com.
About DaVita Clinical Research (DCR) DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita HealthCare Partners, Inc.,uses its extensive, applied database and real-world health care experience to assist pharmaceutical and medical device companies in the design, recruitment and completion of retrospective, prospective and pragmatic clinical trials. DCR's scientific and clinical expertise spans the lifecycle of product development with more than 175 client companies. DCR's early clinical research unit (Phase I-IIa) and late phase clinical research (Phase IIb through post-marketing) network of physicians and investigative sites, real-world health care data, health economics and outcomes research, and medical communications are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit www.davitaclinicalresearch.com.
Media Contact:Bianca ViolanteOffice: (303) 876-6614Mobile: (443)
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Logo - http://photos.prnewswire.com/prnh/20140212/DC63568LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/davita-clinical-research-expands-nephrology-clinical-trial-capabilities-in-europe-300089879.html
SOURCE DaVita Clinical Research
Copyright (C) 2015 PR Newswire. All rights reserved
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
<![CDATA[ <!-- /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black; margin:0in; } --> ]]>
DaVita Clinical Research and Pyxant Labs to Collaborate on Clinical Trials.
